ASCO Annual Meeting: Head and Neck | Conference

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.

Eric J. Sherman, MD, highlights trends he observed with immunotherapy in the head and neck cancer space.

Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.